market access Archives - Page 49 of 50 -

Leela Barham takes a look behind the schemes for patient access in England and puts the case for

Patient Access Schemes: a look behind the scenes

https://pharmaphorum.com/views-and-analysis/patient-access-schemes-a-look-behind-the-scenes/

Articles/ Digital and Social Media/ Views and analysis

Pharma moving to novel digital business models

Andrew McConaghie Digital / Social media, IT / Technology, market access, pharma 0 Comment

The next generation of platforms will be led by industry and not tech companies.

Pharma moving to novel digital business models

https://pharmaphorum.com/views-and-analysis/pharma-moving-to-novel-digital-business-models/

Articles/ Pharma Market Access/ Views and analysis

The shape of market access in pharma: meeting stakeholders’ value needs

Linda Banks market access, pharma 0 Comment

Brand success requires pharma companies to identify and meet the needs of all those involved and communicate where

The shape of market access in pharma: meeting stakeholders’ value needs

https://pharmaphorum.com/views-and-analysis/the-shape-of-market-access-in-pharma-meeting-stakeholders-value-needs/

Articles/ Healthcare/ Pharma Market Access/ Views and analysis

Latin America: ripe potential for pharma

Linda Banks BRIC, emerging markets, Latin America pharma, market access, South America 0 Comment

Trends and opportunities for pharma in Latin America.

Latin America: ripe potential for pharma

https://pharmaphorum.com/views-and-analysis/latin-america-ripe-potential-for-pharma/

Articles/ Market Access/ Views and analysis

Value for money of Health Technology Assessment

Leela Barham Health Technology Assessment, HTA, market access 0 Comment

Health Technology Assessment (HTA), despite the many definitions in use, has become almost synonymous with value for money

Value for money of Health Technology Assessment

https://pharmaphorum.com/views-and-analysis/value-for-money-of-health-technology-assessment/

Articles/ Audio/ Debates/ Debates/ Debates & Insight/ Debates & Insight/ Market Access/ Patients/ Pharma Market Access/ Webinars/ Webinars On demand

Available on-demand: The Price is Right? – Delivering UK access for niche patient populations

Paul Tunnah budget, cancer, CF Trust, debate, drug, England, fund, IMS Health, insight, market access, NHS, orphan, Qualie, rare disease, Shire, Tunnah, UK 0 Comment

With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what

Available on-demand: The Price is Right? – Delivering UK access for niche patient populations

https://pharmaphorum.com/debates-insight-market-access/live-webinar-the-price-is-right-uk-niche-market-access/

Articles/ Views and analysis

Who influences NICE technology appraisals?

Leela Barham market access, NICE 0 Comment

In the world of pharmaceuticals everyone seems to have heard of the National Institute for Health and Care

Who influences NICE technology appraisals?

https://pharmaphorum.com/views-and-analysis/who-influences-nice-technology-appraisals/

Social Network Social Media People Meeting Communication Concept

Articles/ Digital and Social Media/ Pharma Market Access/ UK & Europe/ Views and analysis

Pharma gets social: did digital opinion leaders shape NICE guidance on Xtandi?

Claire bladder cancer, cancer, digital, digital opinion leaders, market access, NICE, Prostate cancer, social media 0 Comment

Digital Opinion Leaders as activists in healthcare decision making.

Pharma gets social: did digital opinion leaders shape NICE guidance on Xtandi?

https://pharmaphorum.com/views-and-analysis/pharma-gets-social-did-digital-opinion-leaders-shape-nice-guidance-on-xtandi/

Pharma Market Access/ UK & Europe/ Video

Executive Perspectives: Jane Griffiths

Rebecca Europe, market access, Transparency 0 Comment

In the latest in our series of interviews with senior executives who are steering the global pharma

Executive Perspectives: Jane Griffiths

https://pharmaphorum.com/video/executive-perspectives-jane-griffiths/

Trending

market access

Login